Spikevax JN.1 Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

SARS-CoV-2 JN.1 mRNA [COVID-19 mRNA vaccine (nucleoside modified)]

Indications/Uses

Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals ≥12 yr.

Click to view Spikevax JN.1 detailed prescribing information

Dosage/Direction for Use

IM Individual ≥12 yr w/ or w/o prior vaccination 1 dose (0.5 mL), administered at least 3 mth after the most recent dose of a COVID-19 vaccine. Individual ≥65 yr 1 dose (0.5 mL). 1 additional dose may be administered at least 3 mth after the most recent dose of a COVID-19 vaccine. Immunocompromised individual ≥12 yr w/ or w/o prior vaccination 1 dose (0.5 mL). Additional age-appropriate dose(s) may be administered at least 2 mth following the most recent dose of a COVID-19 vaccine.

Click to view Spikevax JN.1 detailed prescribing information

Overdosage

View Spikevax JN.1 overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Spikevax JN.1 detailed prescribing information

Special Precautions

Do not administer intravascularly, SC or intradermally. Closely observe for at least 15 min following vaccination. Do not give subsequent doses to those who have experienced anaphylaxis to a prior dose of any Spikevax vaccine. Increased risk for myocarditis & pericarditis following vaccination w/ Spikevax. Postpone vaccination in individuals suffering from acute severe febrile illness or acute infection. Caution in individuals receiving anticoagulant therapy or those w/ thrombocytopenia or any coagulation disorder. Reports of capillary leak syndrome flare-ups in the 1st days after vaccination w/ Spikevax (original). Not intended for childn <12 yr.

Click to view Spikevax JN.1 detailed prescribing information

Use In Pregnancy & Lactation

Click to view Spikevax JN.1 detailed prescribing information

Adverse Reactions

Lymphadenopathy; decreased appetite; irritability/crying; headache, sleepiness; nausea/vomiting; myalgia, arthralgia; inj site pain/swelling/erythema, fatigue, chills, pyrexia. Diarrhoea; rash; inj site urticaria/rash, delayed inj site reaction.

Click to view Spikevax JN.1 detailed prescribing information

Drug Interactions

Administer different injectable vaccines at different inj sites.

Click to view Spikevax JN.1 detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Spikevax JN.1 detailed prescribing information

Storage

View Spikevax JN.1 storage conditions for details to ensure optimal shelf-life.

Description

View Spikevax JN.1 description for details of the chemical structure and excipients (inactive components).

Action

View Spikevax JN.1 mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BN01 - covid-19, RNA-based vaccine ; Belongs to the class of covid-19 vaccines.

Regulatory Classification

P₁S₁S₃

Presentation/Packing

Form

Spikevax JN.1 dispersion for inj 50 mcg/dose (0.5 mL)

Packing/Price

10 × 1's

Spikevax JN.1

Manufacturer:

Moderna

Distributor:

Zuellig